Literature DB >> 20421147

3D MR-spectroscopic imaging assessment of metabolic activity in the prostate during the PSA "bounce" following 125iodine brachytherapy.

Anna Kirilova1, Andrei Damyanovich, Juanita Crook, John Jezioranski, Kris Wallace, Melania Pintilie.   

Abstract

PURPOSE: A temporary increase in prostate-specific antigen (PSA) values is observed in 30%-40% of men following (125)I brachytherapy (BT) for prostate cancer. We present the results of a study to characterize prostate metabolic activity during the PSA "bounce" and to correlate metabolic changes with PSA levels using three-dimensional magnetic resonance spectroscopic imaging (3D-MRSI). METHODS AND MATERIALS: 3D-MRSI was performed in 24 patients during the PSA bounce. Eight of these had also had a baseline 3D-MRSI scan before BT for the purpose of tumor mapping. The 3D-MRSI was repeated at 6- and 12-month intervals, and PSA levels were monitored every 3 months. Twenty-one of the patients had favorable-risk prostate cancer, and 3 had intermediate risk.
RESULTS: The choline+creatine signal intensity, although markedly reduced, was observable following BT. Diffuse activity not corresponding to original biopsy-positive sites was observed in 22 cases, and 2 cases were documented to have local recurrence. No statistically significant correlation between metabolic activity and PSA levels at each interval was found.
CONCLUSION: Post-BT prostate 3D-MRSI shows evidence of diffuse metabolic activity unrelated to residual malignancy. This supports the benign nature of the PSA bounce and suggests an inflammatory etiology. In the situation of a rising PSA, observation of focal activity on MRI/3D-MRSI could be a useful adjunct to suggest local recurrence at an earlier interval after brachytherapy when prostate biopsies would still be unhelpful. Longer follow-up is necessary to confirm the complex relationship between metabolic activity and PSA levels. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421147     DOI: 10.1016/j.ijrobp.2009.10.066

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

Review 2.  MR imaging of treated prostate cancer.

Authors:  Hebert Alberto Vargas; Cecilia Wassberg; Oguz Akin; Hedvig Hricak
Journal:  Radiology       Date:  2012-01       Impact factor: 11.105

Review 3.  A decade in prostate cancer: from NMR to metabolomics.

Authors:  Elita M DeFeo; Chin-Lee Wu; W Scott McDougal; Leo L Cheng
Journal:  Nat Rev Urol       Date:  2011-05-17       Impact factor: 14.432

4.  Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence.

Authors:  Renaud Mazeron; Agathe Bajard; Xavier Montbarbon; Frédéric Gassa; Claude Malet; François Rocher; Sébastien Clippe; Gabriel Bringeon; Olivier Desmettre; Pascal Pommier
Journal:  Radiat Oncol       Date:  2012-03-26       Impact factor: 3.481

5.  Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy.

Authors:  Cian Hackett; Sunita Ghosh; Ron Sloboda; Kevin Martell; Lanna Lan; Nadeem Pervez; John Pedersen; Don Yee; Albert Murtha; John Amanie; Nawaid Usmani
Journal:  J Contemp Brachytherapy       Date:  2014-09-05

6.  Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy.

Authors:  Yoichiro Yamamoto; Chetan P Offord; Go Kimura; Shigehiko Kuribayashi; Hayato Takeda; Shinichi Tsuchiya; Hisashi Shimojo; Hiroyuki Kanno; Ivana Bozic; Martin A Nowak; Željko Bajzer; David Dingli
Journal:  Br J Cancer       Date:  2016-07-12       Impact factor: 7.640

7.  Imaging Biomarkers in Prostate Stereotactic Body Radiotherapy: A Review and Clinical Trial Protocol.

Authors:  Wei Liu; Andrew Loblaw; David Laidley; Hatim Fakir; Lucas Mendez; Melanie Davidson; Zahra Kassam; Ting-Yim Lee; Aaron Ward; Jonathan Thiessen; Jane Bayani; John Conyngham; Laura Bailey; Joseph D Andrews; Glenn Bauman
Journal:  Front Oncol       Date:  2022-04-13       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.